Aspen pays $1b for Merck API business, 11 products
This article was originally published in Scrip
Executive Summary
Johannesburg, South Africa-based Aspen Group will pay $1 billion to acquire an active pharmaceutical ingredient (API) manufacturing business from MSD, known as Merck & Co in the US and Canada, as well as 11 finished products. The deal is meant to bolster Aspen's case in the acquisition of two GlaxoSmithKline blood thinners.